Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa
We have demonstrated in real-world clinical practice that luspatercept is a very effective agent, even in an unselected, pretreated, significantly TD MDS population. The effect was particularly high in the IPSS-M low and very low groups. We believe that the relatively high response rate in our patients was influenced by the frequent use of a higher dose (1.75 mg/kg) and especially by adding ESA to luspatercept in poorly responding patients.
Authors
- Tomáš Stopka (ORCID: https://orcid.org/0000-0001-7236-6894)
- Slavka Sotakova
- Anna Jonášová (ORCID: https://orcid.org/0000-0003-0246-1524)
- Ľubomír Minařík (ORCID: https://orcid.org/0000-0002-1019-2195)
- J Jonas
- Tatiana Aghová (ORCID: https://orcid.org/0000-0002-4184-4678)
- Zuzana Zemanová (ORCID: https://orcid.org/0000-0002-7538-6601)
- Petra Bělohlávková (ORCID: https://orcid.org/0000-0001-8728-7443)
Institutions
- Charles University (CZ)
- Institute of Endocrinology (CZ)
- University Hospital Hradec Králové (CZ)
- The London College (GB)
- General University Hospital in Prague (CZ)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-10-02
- DOI
- https://doi.org/10.3389/fonc.2024.1398331
- Citations
- 5
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 2.27